Track the Takeda Pharmaceutical Company Limited stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Market capitalisation: €52.1bn. The latest transaction was disclosed on 13 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Teresa Bitetti. All data is accessible without an account.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 10,755 of 26,426 companies
56.7
score / 100
Value
79
Quality
35
FCF yld·
Earn yld·
EV/EBITDA6.8x
ROE-2.1%
Gross mgn65%
Net mgn-3.4%
Debt/EBITDA6.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4,319 shares@ US$16.7519100.0% of flowAmerican Depositary Shares (ADSs)SEC144:0001395064-26-000311
13 of 13 declarations
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, specializing in the research and development of innovative medicines. It focuses on therapeutic areas such as oncology, rare diseases, and gastrointestinal disorders.